Scientific

MK5 Microarray Data

Affected Genes - Ontology Breakdown - Gene Enrichment - Proteome Analysis

These are the micro-array results of a differential gene expression microarray experiments and the subsequent analysis steps performed on them. The up/down- regulation ratio was obtained by measuring WT cells against MK5 activated cells. See material and methods for technical information as well as the data usage policy.

MK5 Proteome Analysis

Table 3: Type II network, divided ranks. This table presents the output of the simulation of a type-II network in which we relied on the high confidence interactions and micro-array results. The output of the micro-array was then ranked and these ranks used as input into the network simulation. After performing two such simulations (one for the MK5 off and one for the MK5 on microarray output), we divided the ranks and sorted the results accordingly. The output of this technique is a collection of proteins that cluster naturally together.


Navigation/Query Panel:
Click on the attribute name to hide/unhide it. The green arrows can be used to shift columns left/right. Exact word match is written as =..., regular expressions can be matched with ~.... To select all values larger or equal than use >.... This would be <... for values smaller or equal than. To select all values within a specific range use [...,...].
Rank Gene Hugo description Value Type Network Comparison Type Interaction Map Filtered red green network_comparison
Results: HTML CSV LaTeX Showing element 2358 to 2407 of 3228 in total 
Value Type: Ranked
Network Comparison Type: Divided
Interaction Map: High confidence
Filtered: 1

\def\wcA{0.14285714285714\textwidth}
\def\wcB{0.14285714285714\textwidth}
\def\wcC{0.14285714285714\textwidth}
\def\wcD{0.14285714285714\textwidth}
\def\wcE{0.14285714285714\textwidth}
\def\wcF{0.14285714285714\textwidth}
\begin{longtable}{|c|c|c|c|c|c|}
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
Rank\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
Hugo\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
description\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
red\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
green\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
network\_comparison\vspace{3pt}}\\
\hline
\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2358\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
FKBP8\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
38 kda fk-506 binding protein homolog (fkbpr38) (fk506-binding protein 8). [source:swissprot;acc:q14318]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
198.181\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
197.346\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00423\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2359\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PGK2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
phosphoglycerate kinase, testis specific (ec 2.7.2.3). [source:swissprot;acc:p07205]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
207.196\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
208.056\vspace{3pt}}&\multirow{5}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.00415\vspace{3pt}}}\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2360\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ENO2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
gamma enolase (ec 4.2.1.11) (2-phospho-d-glycerate hydro-lyase) (neural enolase) (nse) (enolase 2). [source:swissprot;acc:p09104]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
207.186\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
208.046\vspace{3pt}}}&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2361\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ENO3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
beta enolase (ec 4.2.1.11) (2-phospho-d-glycerate hydro-lyase) (skeletal muscle enolase) (mse) (enolase 3). [source:swissprot;acc:p13929]\vspace{3pt}}&&&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2362\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PGK1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
phosphoglycerate kinase 1 (ec 2.7.2.3) (primer recognition protein 2) (prp 2). [source:swissprot;acc:p00558]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
207.178\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
208.037\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2363\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ENO1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
alpha enolase (ec 4.2.1.11) (2-phospho-d-glycerate hydro-lyase) (non- neural enolase) (nne) (enolase 1) (phosphopyruvate hydratase). [source:swissprot;acc:p06733]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
207.186\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
208.046\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2364\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TALDO1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
transaldolase (ec 2.2.1.2). [source:swissprot;acc:p37837]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
212.816\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
213.697\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00414\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2365\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
CNDP1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
glutamate carboxypeptidase-like protein 2 precursor. [source:swissprot;acc:q96kn2]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
208.958\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
209.82\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00413\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2366\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HRSP12\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
14.5 kda translational inhibitor protein (p14.5) (uk114 antigen homolog). [source:swissprot;acc:p52758]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
203.353\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
202.529\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.00407\vspace{3pt}}}\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2367\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PSMD11\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
26s proteasome non-atpase regulatory subunit 11 (26s proteasome regulatory subunit s9) (26s proteasome regulatory subunit p44.5). [source:swissprot;acc:o00231]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
217.589\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
218.475\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2368\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PSMD1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
26s proteasome non-atpase regulatory subunit 1 (26s proteasome regulatory subunit s1) (26s proteasome subunit p112). [source:swissprot;acc:q99460]\vspace{3pt}}&\multirow{4}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
218.555\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
219.434\vspace{3pt}}}&\multirow{4}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.00402\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2369\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ADRM1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
adhesion regulating molecule 1 precursor (110 kda cell membrane glycoprotein) (gp110). [source:swissprot;acc:q16186]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2370\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
UCHL5\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ubiquitin carboxyl-terminal hydrolase isozyme l5 (ec 3.4.19.12) (uch- l5) (ubiquitin thiolesterase l5) (ubiquitin c-terminal hydrolase uch37) (cgi-70) (ad-019). [source:swissprot;acc:q9y5k5]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2371\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
C19orf2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
rna polymerase ii subunit 5-mediating protein (rpb5-mediating protein). [source:swissprot;acc:o94763]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2372\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SMAD2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
mothers against decapentaplegic homolog 2 (smad 2) (mothers against dpp homolog 2) (mad-related protein 2) (hmad-2) (jv18-1) (hsmad2). [source:swissprot;acc:q15796]\vspace{3pt}}&\multirow{12}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
212.724\vspace{3pt}}}&\multirow{12}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
213.574\vspace{3pt}}}&\multirow{12}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.004\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2373\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SMAD1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
mothers against decapentaplegic homolog 1 (smad 1) (mothers against dpp homolog 1) (mad-related protein 1) (transforming growth factor- beta signaling protein-1) (bsp-1) (hsmad1) (jv4-1). [source:swissprot;acc:q15797]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2374\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
COPS6\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
cop9 subunit 6 (mov34 homolog, 34 kd). [source:refseq;acc:nm\_006833]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2375\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SMAD3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
mothers against decapentaplegic homolog 3 (smad 3) (mothers against dpp homolog 3) (mad3) (hmad-3) (mmad3) (jv15-2) (hsmad3). [source:swissprot;acc:q92940]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2376\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
HDAC11\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
histone deacetylase 11 (hd11). [source:swissprot;acc:q96db2]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2377\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ETNK2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ethanolamine kinase-like protein eki2 (flj10761). [source:swissprot;acc:q9nvf9]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2378\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ETNK1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ethanolamine kinase (ec 2.7.1.82) (eki). [source:swissprot;acc:q9hbu6]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2379\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TNFSF5IP1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
hepatocellular carcinoma susceptibility protein; x 003 protein; hdcmc29p; hspc260; likely ortholog of mouse cd40 ligand-activated specific transcript 3 (clast3). [source:refseq;acc:nm\_020232]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2380\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
COPS5\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
cop9 constitutive photomorphogenic homolog subunit 5; jun activation domain-binding protein. [source:refseq;acc:nm\_006837]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2381\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SMAD9\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
mothers against decapentaplegic homolog 9 (smad 9) (mothers against dpp homolog 9) (smad9) (madh6). [source:swissprot;acc:o15198]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2382\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
SMAD5\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
mothers against decapentaplegic homolog 5 (smad 5) (mothers against dpp homolog 5) (smad5) (hsmad5) (jv5-1). [source:swissprot;acc:q99717]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2383\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TXN2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
thioredoxin, mitochondrial precursor (mt-trx) (thioredoxin 2). [source:swissprot;acc:q99757]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2384\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MAP2K6\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
dual specificity mitogen-activated protein kinase kinase 6 (ec 2.7.1.-) (map kinase kinase 6) (mapkk 6) (mapk/erk kinase 6) (sapkk3). [source:swissprot;acc:p52564]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
210.57\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
209.737\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00397\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2385\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MAP2K3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
dual specificity mitogen-activated protein kinase kinase 3 (ec 2.7.1.-) (map kinase kinase 3) (mapkk 3) (mapk/erk kinase 3). [source:swissprot;acc:p46734]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
210.595\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
209.767\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00395\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2386\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NDUFB10\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
nadh-ubiquinone oxidoreductase pdsw subunit (ec 1.6.5.3) (ec 1.6.99.3) (complex i-pdsw) (ci-pdsw). [source:swissprot;acc:o96000]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
213.82\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
212.983\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00393\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2387\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PSMB5\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
proteasome subunit beta type 5 precursor (ec 3.4.25.1) (proteasome epsilon chain) (macropain epsilon chain) (multicatalytic endopeptidase complex epsilon chain) (proteasome subunit x) (proteasome chain 6) (proteasome subunit mb1). [source:swissprot;acc:p28074]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
211.301\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
210.475\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00392\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2388\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RNF20\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ring finger protein 20. [source:refseq;acc:nm\_019592]\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
224.414\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
225.289\vspace{3pt}}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.0039\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2389\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
RNF40\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
ring finger protein 40; 95 kda retinoblastoma protein binding protein; likely ortholog of rat staring. [source:refseq;acc:nm\_014771]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2390\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NPEPPS\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
puromycin-sensitive aminopeptidase (ec 3.4.11.-) (psa). [source:swissprot;acc:p55786]\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
214.966\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
215.799\vspace{3pt}}}&\multirow{3}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.00388\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2391\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
LTA4H\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
leukotriene a-4 hydrolase (ec 3.3.2.6) (lta-4 hydrolase) (leukotriene a(4) hydrolase). [source:swissprot;acc:p09960]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2392\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
DHODH\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
dihydroorotate dehydrogenase, mitochondrial precursor (ec 1.3.3.1) (dihydroorotate oxidase) (dhodehase) (fragment). [source:swissprot;acc:q02127]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2393\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
STAM\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
signal transducing adaptor molecule 1; signal transducing adaptor molecule. [source:refseq;acc:nm\_003473]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
182.266\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
182.962\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00382\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2394\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
NAT5\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
n-acetyltransferase 5 (ec 2.3.1.-). [source:swissprot;acc:q9y6d2]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
221.662\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
220.826\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00379\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2395\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PSMC2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
26s protease regulatory subunit 7 (mss1 protein). [source:swissprot;acc:p35998]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
218.192\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
219.014\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00377\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2396\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
YWHAZ\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
14-3-3 protein zeta/delta (protein kinase c inhibitor protein-1) (kcip-1) (factor activating exoenzyme s) (fas). [source:swissprot;acc:p29312]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
220.683\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
221.51\vspace{3pt}}&\multirow{3}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.00375\vspace{3pt}}}\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2397\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
MTIF2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
translation initiation factor if-2, mitochondrial precursor (if-2mt) (if-2(mt)). [source:swissprot;acc:p46199]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
210.157\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
210.945\vspace{3pt}}&\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2398\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PRKCH\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
protein kinase c, eta type (ec 2.7.1.-) (npkc-eta) (pkc-l). [source:swissprot;acc:p24723]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
182.395\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
183.079\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2399\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PRKCE\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
protein kinase c, epsilon type (ec 2.7.1.-) (npkc-epsilon). [source:swissprot;acc:q02156]\vspace{3pt}}&\multirow{5}{*}{\parbox{\wcD}{\vspace{3pt}\noindent
182.4\vspace{3pt}}}&\multirow{5}{*}{\parbox{\wcE}{\vspace{3pt}\noindent
183.083\vspace{3pt}}}&\multirow{5}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.00374\vspace{3pt}}}\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2400\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PPIB\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
peptidyl-prolyl cis-trans isomerase b precursor (ec 5.2.1.8) (ppiase) (rotamase) (cyclophilin b) (s-cyclophilin) (scylp) (cyp-s1). [source:swissprot;acc:p23284]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2401\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
OGT\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
udp-n-acetylglucosamine--peptide n-acetylglucosaminyltransferase 110 kda subunit (ec 2.4.1.-) (o-glcnac transferase p110 subunit). [source:swissprot;acc:o15294]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2402\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
COX4I1\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
cytochrome c oxidase subunit iv isoform 1, mitochondrial precursor (ec 1.9.3.1) (cox iv-1) (cytochrome c oxidase polypeptide iv). [source:swissprot;acc:p13073]\vspace{3pt}}&&&\\\cline{1-3}
\parbox{\wcA}{\vspace{3pt}\noindent
2403\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
COX4I2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
cytochrome c oxidase subunit iv isoform 2, mitochondrial precursor (ec 1.9.3.1) (cox iv-2). [source:swissprot;acc:q96kj9]\vspace{3pt}}&&&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2404\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
ACOX2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
acyl-coenzyme a oxidase 2, peroxisomal (ec 1.3.3.6) (branched-chain acyl-coa oxidase) (brcacox) (trihydroxycoprostanoyl-coa oxidase) (thccox) (thca-coa oxidase). [source:swissprot;acc:q99424]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
193.389\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
194.105\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.0037\vspace{3pt}}\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2405\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
TXNIP\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
thioredoxin interacting protein; upregulated by 1,25-dihydroxyvitamin d-3. [source:refseq;acc:nm\_006472]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
221.677\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
222.489\vspace{3pt}}&\multirow{2}{*}{\parbox{\wcF}{\vspace{3pt}\noindent
1.00366\vspace{3pt}}}\\\cline{1-5}
\parbox{\wcA}{\vspace{3pt}\noindent
2406\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
STAM2\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
signal transducing adaptor molecule 2; stam-like protein containing sh3 and itam domains 2. [source:refseq;acc:nm\_005843]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
182.563\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
183.232\vspace{3pt}}&\\\hline
\parbox{\wcA}{\vspace{3pt}\noindent
2407\vspace{3pt}}&\parbox{\wcB}{\vspace{3pt}\noindent
PSMB3\vspace{3pt}}&\parbox{\wcC}{\vspace{3pt}\noindent
proteasome subunit beta type 3 (ec 3.4.25.1) (proteasome theta chain) (proteasome chain 13) (proteasome component c10-ii). [source:swissprot;acc:p49720]\vspace{3pt}}&\parbox{\wcD}{\vspace{3pt}\noindent
214.234\vspace{3pt}}&\parbox{\wcE}{\vspace{3pt}\noindent
213.456\vspace{3pt}}&\parbox{\wcF}{\vspace{3pt}\noindent
1.00364\vspace{3pt}}\\\hline
nd{longtable}

Legend:
- Rank is the rank after comparing the two networks

 - Gene is the ensembl human gene identifier measured by 1 or more probes on the microarray

 - Hugo is the HGNC identifier if it exists

 - Value Type describes how the microarray measurement was processed. Ranked indicates that we sorted all measurements and use the rank as red and green value. Measured is the normal measurement. Squared and Rooted are the square and square root respecitcely. This might be valueable to compensate for non linear light distributions.

 - Network Comparison Type describes whether we divided the red and green types or whether we sutractcted them

 - Interaction Map specifies whether we used only the hig hconfidence protein-protein interactions or also included the low confidence interactions.

 - Filtered specifies whether we only included the high confidence microarry measurements or not.
- http://analysis.yellowcouch.org/